Intracranial ependymoma: factors affecting outcome

Area of Science:

• Neuro-oncology
• Pediatric neurosurgery
• Molecular pathology

Background:

• Ependymomas represent a significant portion of pediatric central nervous system tumors.
• Current management strategies for intracranial ependymoma yield suboptimal outcomes, with 5-year progression-free survival rates between 30-50%.
• Prognostic factors and optimal treatment pathways remain under investigation.

Purpose of the Study:

• To review the current understanding of ependymoma biology, diagnosis, and treatment.
• To highlight recent molecular findings impacting prognosis and therapeutic strategies.
• To discuss the challenges in achieving optimal patient outcomes.

Main Methods:

• Review of recent scientific literature on ependymomas.
• Analysis of molecular profiles and their correlation with clinical outcomes.
• Evaluation of current treatment modalities and emerging therapeutic approaches.

Main Results:

• Intracranial and spinal ependymomas share molecular similarities with radial glia.
• Gain of 1q25 and EGFR overexpression are associated with poor prognosis.
• Low nucleolin expression correlates with a favorable outcome.
• Complete surgical resection is achievable in approximately 50% of cases.

Conclusions:

• Ependymoma management requires further optimization, particularly for patients with residual disease.
• Molecular markers are crucial for predicting ependymoma prognosis.
• Multimodal treatment, including surgery, radiation, and potentially chemotherapy, is essential for improving outcomes.